TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Beam Therapeutics
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics presented promising clinical trial results for risto-cel, a base editing cell therapy for sickle cell disease, showing high hemoglobin F induction, reduced hemoglobin S, and durable anemia resolution in 31 patients.

Insights
BEAM   positive

Reported strong clinical trial results with high editing efficiency, rapid patient engraftment, and no severe vaso-occlusive crises, indicating promising progress in developing a potential transformative therapy for sickle cell disease